Metabolomics in oncology – A fascinating travel into the mechanisms of metabolic disturbances during carcinogenesis

[1] Beger RD. A review of applications of metabolomics in cancer. Metabolites. 2013 Jul 5;3(3):552–574. BegerRD A review of applications of metabolomics in cancer Metabolites 2013 Jul 5 3 3 552 574 10.3390/metabo3030552390129324958139 Search in Google Scholar

[2] Holmes E., Wilson ID. Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008, 134, 714–717. HolmesE. WilsonID NicholsonJK Metabolic phenotyping in health and disease Cell 2008 134 714 717 10.1016/j.cell.2008.08.02618775301 Search in Google Scholar

[3] Griffin JL., Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4, 551–561. GriffinJL. ShockcorJP Metabolic profiles of cancer cells Nat. Rev. Cancer 2004 4 551 561 10.1038/nrc139015229480 Search in Google Scholar

[4] Spratlin JL., Serkova NJ. Eckhardt SG. Clinical applications of metabolomics in oncology: A review. Clin. Cancer Res. 2009, 15, 431–440. SpratlinJL. SerkovaNJ Eckhardt SG. Clinical applications of metabolomics in oncology: A review Clin. Cancer Res. 2009 15 431 440 10.1158/1078-0432.CCR-08-1059267643719147747 Search in Google Scholar

[5] Vander Heiden, M.G. Targeting cancer metabolism: A therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10, 671–684. Vander HeidenM.G. Targeting cancer metabolism: A therapeutic window opens Nat. Rev. Drug Discov. 2011 10 671 684 10.1038/nrd350421878982 Search in Google Scholar

[6] Armitage EG, Southam AD. Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. Metabolomics. 2016;12(9):146. ArmitageEG SouthamAD Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics Metabolomics. 2016 12 9 146 10.1007/s11306-016-1093-7498738827616976 Search in Google Scholar

[7] Nagrath D, Caneba C, Karedath T, Bellance N. Metabolomics for mitochondrial and cancer studies. Biochim Biophys Acta. 2011 Jun;1807(6):650–663. NagrathD CanebaC KaredathT BellanceN Metabolomics for mitochondrial and cancer studies Biochim Biophys Acta 2011 Jun 1807 6 650 663 10.1016/j.bbabio.2011.03.00621420931 Search in Google Scholar

[8] Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics. 2009 Mar;8(3):558–570. KimK AronovP ZakharkinSO AndersonD PerroudB ThompsonIM WeissRH Urine metabolomics analysis for kidney cancer detection and biomarker discovery Mol Cell Proteomics 2009 Mar 8 3 558 570 10.1074/mcp.M800165-MCP200264981719008263 Search in Google Scholar

[9] Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer. 2005 Feb 20;113(5):782–788. OdunsiK WollmanRM AmbrosoneCB HutsonA McCannSE TammelaJ GeislerJP MillerG SellersT ClibyW QianF KeitzB IntenganM LeleS AlderferJL Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics Int J Cancer 2005 Feb 20 113 5 782 788 10.1002/ijc.2065115499633 Search in Google Scholar

[10] Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol. 2011 Jul;43(7):1002–1009. TeahanO BevanCL WaxmanJ KeunHC Metabolic signatures of malignant progression in prostate epithelial cells Int J Biochem Cell Biol 2011 Jul 43 7 1002 1009 10.1016/j.biocel.2010.07.00320633696 Search in Google Scholar

[11] Dang, L., White, D., Gross, S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009) DangL. WhiteD. GrossS. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate Nature 462 739 744 2009 10.1038/nature08617 Search in Google Scholar

[12] Lane AN, Fan TW, Higashi RM. Isotopomer-based metabolomic analysis by NMR and mass spectrometry. Methods Cell Biol. 2008;84:541–588. LaneAN FanTW HigashiRM Isotopomer-based metabolomic analysis by NMR and mass spectrometry Methods Cell Biol. 2008 84 541 588 10.1016/S0091-679X(07)84018-0 Search in Google Scholar

[13] Mohammed AA. Impact of vitamin D serum levels on clinicopathological features and outcome in advanced pancreatic carcinoma. Forum Clin Oncol 2021; 12 (1): 20–30. MohammedAA Impact of vitamin D serum levels on clinicopathological features and outcome in advanced pancreatic carcinoma Forum Clin Oncol 2021 12 1 20 30 10.2478/fco-2021-0015 Search in Google Scholar

[14] Al-Zeidaneen AS, Ahmad MN, Al-Ebous AD et al. Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status. Forum Clin Oncol 2021; 12 (1): 39–46. Al-ZeidaneenAS AhmadMN Al-EbousAD Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status Forum Clin Oncol 2021 12 1 39 46 10.2478/fco-2019-0018 Search in Google Scholar

[15] Talima S, Kaldas D, Kassem H et al. Prognostic value of cytokines in breast cancer : Correlation with positive hormonal status and obesity. Forum Clin Oncol 2021; 12 (1): 67–73. TalimaS KaldasD KassemH Prognostic value of cytokines in breast cancer : Correlation with positive hormonal status and obesity Forum Clin Oncol 2021 12 1 67 73 10.2478/fco-2021-0001 Search in Google Scholar

[16] Azeez TA, Folorunso SA, Eguzozie EC et al. Antidiabetic drugs and the risk of cancer: beneficial, neutral or detrimental? Forum Clin Oncol 2021; 12 (1): 74–81. AzeezTA FolorunsoSA EguzozieEC Antidiabetic drugs and the risk of cancer: beneficial, neutral or detrimental? Forum Clin Oncol 2021 12 1 74 81 10.2478/fco-2021-0014 Search in Google Scholar